DBV Technologies S.A. (NASDAQ:DBVT) Short Interest Update

DBV Technologies S.A. (NASDAQ:DBVT) saw a large increase in short interest in July. As of July 31st, there was short interest totalling 307,100 shares, an increase of 6.3% from the July 15th total of 288,800 shares. Approximately 0.3% of the company’s shares are sold short. Based on an average trading volume of 94,100 shares, the days-to-cover ratio is presently 3.3 days.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on DBVT shares. StockNews.com began coverage on shares of DBV Technologies in a research note on Sunday. They set a “hold” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of DBV Technologies in a research report on Thursday, August 1st. Finally, JMP Securities lifted their target price on DBV Technologies from $4.00 to $5.00 and gave the company a “market outperform” rating in a report on Wednesday, July 31st.

Institutional Investors Weigh In On DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Cowen AND Company LLC purchased a new stake in DBV Technologies S.A. (NASDAQ:DBVT) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 50,986 shares of the company’s stock, valued at approximately $49,000. 71.74% of the stock is owned by hedge funds and other institutional investors.

DBV Technologies Price Performance

Shares of DBVT traded down $0.01 during midday trading on Friday, reaching $0.93. The stock had a trading volume of 5,736 shares, compared to its average volume of 51,975. DBV Technologies has a 1-year low of $0.50 and a 1-year high of $3.70. The company has a market cap of $89.98 million, a price-to-earnings ratio of -1.11 and a beta of 0.68. The company’s fifty day simple moving average is $0.91 and its two-hundred day simple moving average is $1.26.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings results on Tuesday, July 30th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.08). The company had revenue of $1.16 million during the quarter, compared to analysts’ expectations of $1.42 million. DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. During the same quarter in the prior year, the company earned ($0.26) earnings per share. On average, sell-side analysts forecast that DBV Technologies will post -1.22 earnings per share for the current year.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.